Insulinoma Clinical Trial
Official title:
Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors
Verified date | June 2013 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.
Status | Terminated |
Enrollment | 25 |
Est. completion date | |
Est. primary completion date | October 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed carcinoid tumor or islet cell neuroendocrine tumor - Well- or moderately-differentiated tumor - Metastatic and/or locally advanced disease - Measurable disease - Unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan - Lesions in a previously irradiated area are not considered measurable - No truly non-measurable lesions, including the following: - Bone lesions - Leptomeningeal disease - Ascites - Pleural or pericardial effusion - Lymphangitis cutis/pulmonis - Abdominal masses not confirmed and followed by imaging - Cystic lesions - Ineligible for standard treatment - Performance status - ECOG 0-1 - At least 6 months - WBC >= 3,000/mm^3 - Absolute neutrophil count >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - Bilirubin =< 1.5 mg/dL - AST and ALT =< 2.5 times upper limit of normal - Creatinine =< 1.5 mg/dL - No New York Heart Association class III or IV congestive heart failure - No myocardial infarction within the past year - No uncontrolled dysrhythmias - No poorly controlled angina - No serious ventricular arrhythmia, defined as ventricular tachycardia or ventricular fibrillation >= 3 beats in a row - No left ventricular hypertrophy by EKG - No other significant cardiac disease - QTc < 500 msec - LVEF > 40% by resting MUGA - No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drug - No ongoing or active infection - No psychiatric illness or social situation that would preclude study compliance - No other concurrent uncontrolled illness - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - More than 4 weeks since prior immunotherapy (e.g., interferon alfa) - More than 4 weeks since prior chemotherapy - More than 12 weeks since prior hepatic artery chemoembolization unless liver lesions are not the only indicator lesions - No prior FR901228 (depsipeptide) - No more than 1 prior systemic chemotherapy regimen for carcinoid or islet cell tumor (other than hepatic artery chemoembolization) - More than 4 weeks since prior oral or IV steroids (first 16 patients only) - Concurrent long-acting octreotide allowed at standard doses if dose has been stable for the past 12 weeks - Concurrent subcutaneous octreotide for breakthrough use for symptomatic relief allowed - No concurrent systemic steroids (first 16 patients only) - More than 4 weeks since prior radiotherapy - More than 4 weeks since prior investigational tumor-specific therapy - No other prior histone deacetylase inhibitors (e.g., valproic acid) - No concurrent hydrochlorothiazide - No concurrent combination antiretroviral therapy for HIV-positive patients - No other concurrent investigational or commercial agents or therapies for the malignancy |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Medical Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate | Frequency of response will be estimated with a 95% confidence interval. | Up to 4 weeks | No |
Secondary | Incidence of toxicity | Up to 4 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02021604 -
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
|
Phase 1 | |
Withdrawn |
NCT02108782 -
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT05034783 -
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
|
Early Phase 1 | |
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Completed |
NCT00937079 -
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|
Phase 1 | |
Recruiting |
NCT04185350 -
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
|
Early Phase 1 | |
Recruiting |
NCT00001276 -
Diagnosing and Treating Low Blood Sugar Levels
|
||
Active, not recruiting |
NCT02121366 -
EUS-guided Ethanol Ablation of an Insulinoma
|
N/A | |
Completed |
NCT00131911 -
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00005910 -
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
|
N/A | |
Recruiting |
NCT03583528 -
DOTATOC PET/CT for Imaging NET Patients
|
||
Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
Recruiting |
NCT05523778 -
A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
|
N/A | |
Recruiting |
NCT02560376 -
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
|
Phase 0 | |
Completed |
NCT01525082 -
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00655655 -
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00075439 -
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT04452396 -
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
|
N/A | |
Active, not recruiting |
NCT01824875 -
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 |